Sunresin New Materials Co., Ltd. (300487.SZ) develops, manufactures and sells adsorption and separation materials, ion exchange resins, chromatographic media and integrated separation equipment including Sepsolut systems; offers technical services and customized solutions for industries such as biopharmaceuticals, life sciences, food processing, pharmaceuticals, plant extraction, hydrometallurgy, wastewater treatment, membrane caustic soda and industrial water treatment. The company produces over 30 series and more than 200 resin types with annual capacity exceeding 50,000 cubic meters, alongside tens of adsorption and separation equipment units. Founded in 2001 and headquartered in Xi'an High-Tech Industrial Development Zone, Shaanxi Province, China, Sunresin operates production bases in Xi'an, Weinan, Hebi and Belgium, with sales reaching over 100 countries globally.
Sunresin recently established subsidiaries in Sweden as its life sciences European headquarters with Hans Johansson as general manager, launched Sunresin USA Inc. to enhance North American supply chain capabilities, and announced a USD 160 million investment for a new life sciences industrial park in Pucheng covering 18 hectares to boost chromatography resins and advanced materials production including a GMP facility for APIs and excipients; expanded strategic collaboration with ChiralVision on immobilized enzyme technologies, secured Australian patent for lithium adsorbent, achieved DMF registrations for 10 bioprocess resins supporting antibody, vaccine and gene therapy applications, and reported 2024 revenue of RMB 2.55 billion up 2.6% with net profit of RMB 794 million up 10.1% driven by 33-34% volume growth in hydrometallurgy, life sciences, water treatment and 45% overseas sales increase.